The Problem

Woman Hospital Drinking Water

No Approved

Multiple Failures

Multiple failures due to lack of efficacy and/or adverse events

Market Focus

Market focus is on F2-F4 patients.

  • No drug development emphasis on F1 or decompensated liver patients.
  • The patients don’t “feel” sick, making compliance an issue
  • No drug candidates for decompensated liver disease


NASH is highly complex disease that can cause a severely compromised lifestyle and even death – a targeted and multi-pronged approach is required for success.

Current Therapies

The problems with these (current) therapies: “Several pathways are implicated to play a role in NASH pathophysiology from the progression of normal liver fat levels to steatohepatitis and, consequently, fibrosis of the liver.” (Global Market Data, 2020)

Learn about the Solution